Appendix 1 – Cancer Diagnosis and Procedure Codes



Appendix 1 – Cancer Diagnosis and Procedure Codes

|Type of Malignant Tumor |ICD-9-CM Diagnosis Codes |ICD-9-CM Procedure Codes |CPT-4 Procedure Codes |

|Bone |170.0-170.9 |84.0-84.19 |23900-23921, 24900-24940, 25900-25931, 26910-26952, 27290, 27295, |

| | | |27590-27598, 27880-27889, 28800-28825 |

|Brain and Other Central Nervous System |191.0-192.3 |01.1-01.59 |61510, 61516, 61518, 61520, 61521, 61524, 61526, 61530, 61534, 61536, 61544,|

| | | |61545 |

|Breast |174.0-175.9 |84.4-85.48, 85.20-85.23 |19120, 19125, 19126, 19160, 19162, 19180-19240 |

|Cervix Uteri |180.0-180.9 |68.3-68.9 |57530, 57531, 58150, 58180, 58200, 58210, 58240, 58260, 58262, 58275, 58285,|

| | | |58940 |

|Colon and Rectum |153.0-154.8 |45.71-45.79, 45.8, 48.5, 48.62, 48.63 |44140, 44141, 44143, 44144, 44145-44147, 44150-44153, 44155, 44156, 44160, |

| | | |45110-45114, 45116, 45119 |

|Corpus Uteri |179, 182.0-182.8 |68.3-68.9 |58150, 58180, 58200, 58210, 58240, 58260, 58262, 58275, 58285, 58940 |

|Esophagus |150.0-150.9 |42.4-42.69 |43107-43124 |

|Hodgkins Lymphoma |201.0-201.9 |Chemotherapy and/or radiation therapy * |Chemotherapy and/or radiation therapy * |

|Non-Hodgkins Lymphoma |200.0-200.8, 202.0-202.9 |Chemotherapy and/or radiation therapy * |Chemotherapy and/or radiation therapy * |

|Kaposi Sarcoma |176.0-176.9 |Chemotherapy and/or radiation therapy * |Chemotherapy and/or radiation therapy * |

|Kidney and Renal Pelvis |189.0-189.9 |55.4-55.54, 56.4-56.51 |50220-50240, 50650, 50660 |

|Larynx |161.0-161.9 |25.2-25.4, 29.33, 30.1-30.4 |31360-31420, 41120-41155, 42120, 42410-42426 |

|Leukemia |205.0-208.9 |Chemotherapy and/or radiation therapy * |Chemotherapy and/or radiation therapy * |

|Liver and Intrahepatic Bile Duct |155.0-155.2, 156.0-156.9 |50.22, 50.3, 50.4, 51.36 |47120-47130, 47711, 47712, 47760, 47765, 47780, 47785, 47800 |

|Lung and Bronchus |162.0-163.9 |32.29, 32.3, 32.4, 32.5, 32.6, 32.9 |47120-47130, 47711, 47712, 47760, 47765, 47780, 47785, 47800 |

|Melanoma |172.0-172.9 |86.24, 86.4 |11600-11646, 17260-17286, 17304-17310 |

|Mesothelioma |163.0-163.9 |32.29, 32.3, 32.4, 32.5, 32.6, 32.9 |32440, 32442, 32445, 32480, 32482, 32484, 32486, 32488, 32500, 32520, 32522,|

| | | |32525, 32657, 32663 |

|Myeloma |203.0, 238.6 |Chemotherapy and/or radiation therapy * |Chemotherapy and/or radiation therapy * |

|Oral Cavity and Pharynx |140.0-149.9 |25.2-25.4, 29.33, 30.1-30.4 |31360-31420, 41120-41155, 42120, 42410-42426 |

|Ovary |183.0-183.9 |65.0, 65.4, 65.5, 65.6, 68.3-68.9 |58150, 58180, 58200, 58210, 58240, 58260, 58262, 58275, 58285, 58940, 58943,|

| | | |58950-58952, 58960 |

|Pancreas |157.0-157.3, 157.8, 157.9 |44.39, 51.36, 51.39, 51.42, 52.50-52.79;6 |43820, 43825, 47720 - 47790, 48140-48144, 48146, 48147, 48149 - 48155 |

|Prostate |185 |60.5, 62.4-62.42 |54520, 54530, 55810-55815, 55840-55845 |

|Stomach |151.0-151.9 |42.5-43.99 |43620-43634, 43638 |

|Testis |186.0-186.9 |62.3, 62.4 |54520, 54535, 54690 |

|Thyroid |193 |06.11-06.12, 06.2-06.52 |60210-60271 |

|Urinary Bladder |188.0-188.9 |57.33, 57.4, 57.49, 57.71, 57.79 |51570, 51575, 51580-51597, 51720, J8520, J8521 |

* Chemotherapy was defined by ICD-9-CM codes 99.25, V58.1, V66.2, or V67.2, CPT-4 codes 96400-96549, J9000-J9999, and Q0083-Q0085 and revenue center codes of 0331, 0332, and 0335. Radiation therapy was defined by ICD-9-CM diagnosis codes V58.0, V 66.1 and V 67.1, ICD-9-CM procedure codes 92.2-92.39, CPT-4 codes of 77261-77431, 77499, 77750-77799 and revenue center codes of 0330 and 0333.

Appendix 2 – Results of Analyses Using Definition of Two or More Diagnosis Codes for Incident Cancer

|  |  |BMP Treatment |p value |

| |Full Cohort |NO |YES | |

| |n |% |

|MALE |49003 |33.5 |

|67-69 |28187 |19.3 |

|White |137023 |93.7 |

|0 |59213 |40.5 |

|2003 |1898 |1.3 |

|Any Cancer |18942 |13.0 |16309 |13.1 |2633 |12.0 |

Risk of Cancer Associated with BMP Administration in Unadjusted and Adjusted Models Using Definition of Two or More Diagnosis Codes for Incident Cancer

|  | | | | | | |

|  | | |

| |Crude Hazard Ratio |Adjusted Hazard Ratio |

| |HR |95%CI |HR |95%CI |

|Diagnosis in Follow Up |  | |  |  | |  |

|Any Cancer |0.97 |0.93 |1.01 |

| | |NO |YES | |

| |n |% |n |% |n |% |

Risk of Cancer Associated with BMP Administration in Unadjusted and Adjusted Models Using Definition of Two or More Diagnosis Codes and One or More Treatment Codes for Incident Cancer

|  |Diagnosis code + treatment |Diagnosis code + treatment |

| |Crude Hazard Ratio |Adjusted Hazard Ratio |

| |HR |95%CI |HR |95%CI |

|Diagnosis in Follow Up |  |  |  |  |  |  |

|Any Cancer |0.94 |0.89 |0.98 |0.95 |0.90 |0.99 |

|Bone |0.93 |0.68 |1.26 |0.94 |0.69 |1.27 |

|Brain |0.65 |0.46 |0.90 |0.64 |0.46 |0.90 |

|Breast |0.98 |0.88 |1.08 |0.97 |0.88 |1.08 |

|Cervix Uteri |0.80 |0.46 |1.39 |0.79 |0.45 |1.38 |

|Colon and Rectum |0.96 |0.82 |1.12 |0.97 |0.83 |1.13 |

|Corpus Uteri |0.83 |0.59 |1.16 |0.83 |0.59 |1.17 |

|Esophagus |0.97 |0.64 |1.47 |0.99 |0.65 |1.50 |

|Hodgkins Lymphoma |1.23 |0.74 |2.04 |1.24 |0.75 |2.06 |

|Non Hodgkins Lymphoma |1.05 |0.88 |1.26 |1.06 |0.89 |1.27 |

|Kaposi Sarcoma |0.38 |0.05 |2.88 |0.38 |0.05 |2.84 |

|Kidney and Renal Pelvis |0.82 |0.64 |1.05 |0.83 |0.64 |1.06 |

|Larynx |0.68 |0.38 |1.20 |0.69 |0.39 |1.22 |

|Leukemia |0.84 |0.60 |1.18 |0.85 |0.61 |1.19 |

|Liver and Intrahepatic Bile Ducts |1.26 |0.93 |1.71 |1.27 |0.93 |1.72 |

|Lung and Bronchus |1.00 |0.88 |1.13 |1.00 |0.88 |1.13 |

|Melanoma |0.98 |0.85 |1.14 |1.01 |0.87 |1.17 |

|Mesothelioma |1.00 |0.47 |2.11 |1.01 |0.48 |2.13 |

|Myeloma |0.82 |0.62 |1.08 |0.83 |0.63 |1.09 |

|Oral Cavity and Pharnyx |0.81 |0.35 |1.89 |0.83 |0.36 |1.95 |

|Ovary |1.03 |0.76 |1.38 |1.02 |0.76 |1.38 |

|Pancreas |1.23 |0.95 |1.59 |1.23 |0.95 |1.60 |

|Prostate |0.94 |0.83 |1.06 |0.94 |0.83 |1.06 |

|Stomach |1.05 |0.76 |1.46 |1.06 |0.77 |1.48 |

|Testis |1.40 |0.53 |3.69 |1.40 |0.53 |3.70 |

|Thyroid |1.01 |0.66 |1.54 |0.99 |0.65 |1.52 |

|Urinary Bladder |0.90 |0.73 |1.11 |0.93 |0.76 |1.15 |

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download